Pierre Fabre Pharma GmbH clinical trials
A country office of Pierre Fabre
The registry lists 7 studies whose lead sponsor is Pierre Fabre Pharma GmbH. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 6, 2025.
Registry sponsor names on this page
- Pierre Fabre Pharma GmbH6 studies
- Pierre Fabre Pharma AG1 study
Something wrong with this grouping? Tell us on the Pierre Fabre page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Pierre Fabre studies →
- BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC TreatmentRecruitingNCT04673955
Sponsor listed in the registry: Pierre Fabre Pharma GmbH
- Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma TreatmentRecruitingNCT04045691
Sponsor listed in the registry: Pierre Fabre Pharma GmbH
- Real-life Pan-HER-blockade With NeratinibCompletedNCT04388384
Sponsor listed in the registry: Pierre Fabre Pharma GmbH
- Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).CompletedNCT04318405
Sponsor listed in the registry: Pierre Fabre Pharma AG
- Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and AustriaCompletedNCT02619929
Sponsor listed in the registry: Pierre Fabre Pharma GmbH
- JAVLOR® Online Non-Interventional TrialCompletedNCT01103544
Sponsor listed in the registry: Pierre Fabre Pharma GmbH
- Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)CompletedNCT00890903
Sponsor listed in the registry: Pierre Fabre Pharma GmbH